Daniel J Drucker (@DanielJDrucker) header
Daniel J Drucker (@DanielJDrucker) profile picture

A clinician scientist at LTRI @sinaihealth studying GLP-1, diabetes, obesity and the gut endocrine system Proud 🇨🇦Not going anywhere Am 🇮🇱Chai

Toronto
Joined May 2011
Photo by Daniel J Drucker (@DanielJDrucker)Photo by Daniel J Drucker (@DanielJDrucker)Photo by Daniel J Drucker (@DanielJDrucker)Photo by Daniel J Drucker (@DanielJDrucker)Photo by Daniel J Drucker (@DanielJDrucker)Photo by Daniel J Drucker (@DanielJDrucker)Photo by Daniel J Drucker (@DanielJDrucker)Photo by Daniel J Drucker (@DanielJDrucker)Photo by Daniel J Drucker (@DanielJDrucker)Photo by Daniel J Drucker (@DanielJDrucker)
Daniel J Drucker retweeted
Stopping GLP-1 treatment linked to twice the risk of heart attack, stroke or death compared with continuing, in people with type 2 diabetes and no cardiovascular disease, according to a new study. Find out more in @LancetRH_Europe: spkl.io/60137wUtS
62
246
92
805
380,070
Daniel J Drucker retweeted
GLP-1 peptides protect the gut from immune injury. Essential role of endogenous GLP-1 family peptides to reduce inflammation and restore mucosal integrity in the experimental model @DanielJDrucker @CellRepMed cell.com/cell-reports-medici…
22
93
5
410
35,621
Daniel J Drucker retweeted
SCOOP: Top researchers at Columbia, Stanford, and others thought they were elected to elite scientific societies alongside Nobel laureates. The catch? The organizations are a sham. I spent the last month investigating a massive academic scam, for @Nature nature.com/articles/d41586-0…
12
184
30
499
151,928
Daniel J Drucker retweeted
The GLP-1 drugs have evidence for beneficial impact— heart, kidney, liver, joints, immune system, and brain—that are independent of weight loss @Cell_Metabolism @DanielJDrucker cell.com/cell-metabolism/abs…
40
272
16
1,144
149,509
Daniel J Drucker retweeted
3
29
3
258
184,532
Daniel J Drucker retweeted
2026 Obesity Prize for Excellence Winner - Professor Sadaf Farooqi 🏆 Watch this excellent short video and learn more about her research ➡️ Beyond willpower: the biological basis of weight regulation. eco-newsletter.co.uk/article…
6
21
1,638
Daniel J Drucker retweeted
At 3 years, NAION was more frequent among people who started GLP-1 drugs: â–¸ GLP-1 drugs: 39.1 cases per 10,000 persons â–¸ SGLT2 inhibitors: 29.3 cases per 10,000 persons That works out to 6 to 10 extra cases per 10,000. A 35% higher risk on GLP-1.
6
7
30
5,619
Daniel J Drucker retweeted
🏆 We're proud to announce Prof. Anette Ziegler as the recipient of the 58th EASD Claude Bernard Prize: the highest honour our association bestows. Her career has been driven by 1 vision: a world w/out #T1D. Join us in celebrating her at #EASD2026. 🔗👉easd.org/prizes/claude-berna…
9
13
1,299
Daniel J Drucker retweeted
With great sadness I report the passing of my scientific mentor Jesse Roth at age 91. Jesse was a brilliant & innovative scientist who led the field of membrane receptor biology from NIH diabetes branch. A small part of that family tree is shown. May his memory be a blessing.
5
14
4
55
8,306
Daniel J Drucker retweeted
Whoever’s making fun are clearly idiots! Come and sit in clinic with me and feel good that we have more solutions for those who don’t to lose any weight on 15mg of tirzepatide or who have side effects and cannot tolerate it. A suite of options are needed - I’m super happy Novo did this trial.
Everyone is making fun of Novo for doing this trial. I think it should be applauded that big pharma took a swing even though they missed. Science won. Investors did not.
4
5
90
15,729
Daniel J Drucker retweeted
I wouldn't call 23% a miss. SURMOUNT-1 data reminds us that tirzepatide did not work for weight loss in ~10% of people. All of my patients who didn't see significant #weightloss with tirzepatide will be trialed on CagriSema. Amylin introduces a different mechanism. The differentiation here will unmask the heterogeneity of #obesity
Everyone is making fun of Novo for doing this trial. I think it should be applauded that big pharma took a swing even though they missed. Science won. Investors did not.
17
25
2
215
33,988
🚀 We are live! The website for the 13th Helmholtz Diabetes Conference is now online! Explore the speaker list and key information on the meeting on 21–23 September! Program & registration coming soon. 👉 helmholtz-munich.de/en/diabe… #SaveTheDate #StayTuned #HelmholtzDiabetes2026
1
5
2
11
1,986
Daniel J Drucker retweeted
Today, the FDA is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies — including Hims & Hers and other compounding pharmacies — as similar alternatives to FDA-approved drugs. fda.gov/news-events/press-an…
144
135
132
817
367,751
For readers interested in GLP-1-based therapies for obesity and beyond, such as Roche's candidate CT-388, here's a comprehensive review nature.com/articles/s41573-0… rdcu.be/e09xH
4
44
1
214
17,488
Daniel J Drucker retweeted
Can GLP-1 drugs reduce the incidence of cancer, independent of weight loss? Results from cohort studies are encouraging for many types (Figure) and clinical trials are ongoing @NatureCancer nature.com/articles/s43018-0…
19
218
20
800
68,157
Daniel J Drucker retweeted
The gastrointestinal side effects of GLP-1 drugs are mediated by the brain, not the gut. The gut-brain axis at work @jclinicalinvest jci.org/articles/view/194744
7
164
6
625
51,270